Aurobindo Pharma Ltd Share Price, Fundamentals and Financials

Aurobindo Pharma Ltd is an Indian pharmaceutical company that manufactures and markets generic medicines, active pharmaceutical ingredients, specialty products, injectables, biosimilars and related healthcare products across India and international markets. Customers should use medicines only as prescribed by qualified healthcare professionals.

This page helps retail investors and interested customers track the latest available Aurobindo Pharma share price, 52 week high and low, chart trend, basic fundamentals, financial highlights, shareholding pattern, peer comparison and corporate action history in one place.

Aurobindo Pharma earns revenue by developing, manufacturing and selling generic formulations, active pharmaceutical ingredients, specialty products and related pharmaceutical products. Its performance depends on product approvals, regulated-market demand, manufacturing compliance, pricing, currency movements, input costs and execution in key markets.

Aurobindo Pharma has a large international presence with business exposure to the United States, Europe, growth markets and India. The United States generics market is especially important, so investors often monitor US product approvals, pricing pressure and regulatory inspections.

An API, or active pharmaceutical ingredient, is the core ingredient that makes a medicine work. A formulation is the finished medicine form such as a tablet, capsule, injectable or other dosage form. Aurobindo Pharma operates across both areas, which can help with scale and supply-chain control.

The company is commonly tracked across formulations, APIs, specialty and injectable products, biosimilars and peptide-related opportunities, along with geographic segments such as the US, Europe, growth markets and India. Investors should verify the latest segment reporting from annual reports and exchange filings.

Key risks include USFDA and other regulatory observations, product approval delays, generic price erosion, high dependence on export markets, currency movement, raw material costs, plant compliance, litigation, debt, acquisition integration and changes in healthcare regulations.

The 52 week high and low show the highest and lowest traded prices during the last one year. They help users understand the recent price range, but they do not indicate whether the stock is cheap or expensive by themselves. Investors should also study earnings, valuations, balance sheet strength and risks.

Aurobindo Pharma has declared dividends in some past years, but dividend amount, record date and payout can change based on board decisions, profits, cash flows and shareholder approvals. Always verify the latest dividend details from NSE, BSE and company filings before relying on them.

Aurobindo Pharma has a past history of bonus issues and stock splits. Corporate actions affect historical per-share data, so investors should verify the latest bonus, split and face value details from official exchange filings before making calculations.

Aurobindo Pharma can be compared with other pharma companies on revenue mix, US exposure, product pipeline, regulatory record, margins, return ratios, debt, cash flow, valuation, dividend yield and long-term growth. Peer comparison should be updated frequently because market prices and valuations change daily.

USFDA inspections matter because the United States is a major regulated market for generic medicines. Any warning letter, import alert, observation or remediation update can influence product launches, exports, costs and investor sentiment.

Investors commonly track revenue growth, operating margin, net profit, R&D spending, US sales trend, Europe and growth-market performance, API performance, debt, cash flow, working capital, capital expenditure and management commentary on regulatory status.

No. This page is for educational and informational use only. It does not provide a buy, sell or hold recommendation. Investors should consult a SEBI-registered investment adviser and verify the latest official data before making investment decisions.

Users should verify the latest quarterly results, annual reports, shareholding pattern, dividend, bonus, split, board meeting and corporate action details from the company investor relations website, NSE, BSE and official exchange filings.